INmune Bio Inc. (INMB)
7.78
0.26 (3.46%)
At close: Mar 31, 2025, 3:59 PM
7.77
-0.12%
After-hours: Mar 31, 2025, 06:38 PM EDT
3.46% (1D)
| Bid | 7.25 |
| Market Cap | 206.88M |
| Revenue (ttm) | 55.33K |
| Net Income (ttm) | -54.37M |
| EPS (ttm) | -2.11 |
| PE Ratio (ttm) | -3.69 |
| Forward PE | -3.92 |
| Analyst | Buy |
| Ask | 8.05 |
| Volume | 308,701 |
| Avg. Volume (20D) | 386,344 |
| Open | 7.66 |
| Previous Close | 7.52 |
| Day's Range | 7.38 - 7.80 |
| 52-Week Range | 4.32 - 12.72 |
| Beta | 1.94 |
About INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic synd...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2019
Employees 13
Stock Exchange NASDAQ
Ticker Symbol INMB
Website https://www.inmunebio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for INMB stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 195.63% from the latest price.
Stock Forecasts1 month ago
+10.67%
Inmune Bio shares are trading higher after the com...
Unlock content with
Pro Subscription
5 months ago
+13.84%
INmune Bio shares are trading higher after the company announced it will host a webinar on cognitive testing using EMACC and CDR-SB on November 7 at 1 pm ET.
